Although the association between CLRs and IL-27 in bladder cancer has not been fully elucidated, we can speculate that this potential pathway could be utilized by tumor cells to promote the expression of a variety of immune-checkpoint proteins and further facilitate the formation of immune resistance. Here, LARS1 is linked to urinary bladder carcinoma.